###begin article-title 0
Meta-Analysis and Gene Set Enrichment Relative to ER Status Reveal Elevated Activity of MYC and E2F in the "Basal" Breast Cancer Subgroup
###end article-title 0
###begin p 1
Conceived and designed the experiments: MCA MGG DJN CJO. Performed the experiments: MCA MGG. Analyzed the data: MCA MGG RS EAM CJO. Contributed reagents/materials/analysis tools: YW JAF RS EAM. Wrote the paper: MCA MGG RS EAM CJO. Funded study: CJO.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Breast cancers lacking the estrogen receptor (ER) can be distinguished from other breast cancers on the basis of poor prognosis, high grade, distinctive histopathology and unique molecular signatures. These features further distinguish estrogen receptor negative (ER-) tumor subtypes, but targeted therapy is currently limited to tumors over-expressing the ErbB2 receptor.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
To uncover the pathways against which future therapies could be developed we undertook a meta-analysis of gene expression from five large microarray datasets relative to ER status. A measure of association with ER status was calculated for every Affymetrix HG-U133A probe set and the pathways that distinguished ER- tumors were defined by testing for enrichment of biologically defined gene sets using Gene Set Enrichment Analysis (GSEA). As expected, the expression of the direct transcriptional targets of the ER was muted in ER- tumors, but the expression of genes indirectly regulated by estrogen was enhanced. We also observed enrichment of independent MYC- and E2F-driven transcriptional programs. We used a cell model of estrogen and MYC action to define the interaction between estrogen and MYC transcriptional activity in breast cancer. We found that the basal subgroup of ER- breast cancer showed a strong MYC transcriptional response that reproduced the indirect estrogen response seen in estrogen receptor positive (ER+) breast cancer cells.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
Increased transcriptional activity of MYC is a characteristic of basal breast cancers where it mimics a large part of an estrogen response in the absence of the ER, suggesting a mechanism by which these cancers achieve estrogen-independence and providing a potential therapeutic target for this poor prognosis sub group of breast cancer.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 169 172 169 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Sims1">[1]</xref>
###xml 234 237 234 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Early1">[2]</xref>
###xml 420 423 420 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Early1">[2]</xref>
###xml 525 526 525 526 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 650 658 <span type="species:ncbi:9606">patients</span>
###xml 845 853 <span type="species:ncbi:9606">patients</span>
Breast cancers are routinely classified into estrogen receptor positive (ER+) and estrogen receptor negative (ER-). These tumor types have distinct molecular phenotypes [1]. ER+ cancers may respond to anti-estrogens such as tamoxifen [2], although a significant proportion demonstrate resistance to endocrine therapy. ER- tumors fail to respond to endocrine therapy and have a poor prognosis when compared to ER+ tumors [2]. The genetic pathways utilized by ER- tumors to proliferate in the absence of a mitogenic estrogen (E2) signal are poorly understood. Elucidation of these pathways is required for the development of improved therapies for ER- patients. Currently the only targeted therapy for ER- tumors is a monoclonal antibody against the ErbB2 receptor (ERBB2), Herceptin, which is indicated in ER-/Progesterone Receptor (PGR)-/ERBB2+ patients. The genetic mechanisms responsible for proliferation in ER- tumors could also allow ER+ tumors to exhibit intrinsic or acquired endocrine resistance and so develop a functional ER- tumor status.
###end p 9
###begin p 10
###xml 111 114 111 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Gruvberger1">[3]</xref>
###xml 115 118 115 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Schneider1">[5]</xref>
###xml 335 338 335 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Sims1">[1]</xref>
###xml 488 491 488 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Abba1">[4]</xref>
Several studies have defined sets of genes with differential expression levels between ER+ and ER- tumor types [3]-[5]. Others have defined the smallest gene set that discriminates between molecular subtypes such as luminal (predominantly ER+), ERBB2+ and molecular basal (predominantly high grade/ER-/PGR-/ERBB2-/basal cytokeratin +) [1], with a view to producing better prognostic markers. These gene sets show a small overlap restricted to only the most differentially expressed genes [4], preventing the definition of common pathways. Integration of data from multiple studies by a meta-analysis provides the statistical power necessary to define common genetic pathways and to provide new biological insight into the cause of phenotypic diversity in breast cancer. A meta-analysis minimizes individual study biases, and identifies genes with small but consistent expression changes that might not have passed significance thresholds in individual studies.
###end p 10
###begin p 11
###xml 673 676 673 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Dennis1">[6]</xref>
###xml 773 776 773 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Subramanian1">[7]</xref>
We have conducted a meta-analysis of five independent breast cancer cohorts with the objective of producing a comprehensive measure of differential expression between ER+ and ER- tumors for every probe set on the Affymetrix HG-U133A chip. We present the first study with sufficient numbers of tumors to separate the confounding effects of grade and ER status. The genetic pathways and mechanisms active in ER+ and ER- tumors were elucidated using two different approaches to functional annotation analysis of the meta-analysis results - testing for over-representation of functional categories using Database for Annotation, Visualization, and Integrated Discovery (DAVID) [6], and for enrichment of public and in-house gene lists using gene set enrichment analysis (GSEA) [7]. We related the functional annotation and GSEA results to the subtypes of breast cancer in three independent validation datasets. We show that enhanced transcriptional activity of MYC within the basal subgroup of ER- breast cancer mimics aspects of the transcriptional response to estrogen seen in ER+ cancers. This finding provides a mechanism that allows ER- tumors to overcome the absence of ER and establishes MYC and its transcriptional targets as candidates for the development of novel therapies for the basal subgroup of breast cancer.
###end p 11
###begin title 12
Materials and Methods
###end title 12
###begin title 13
Data Collection
###end title 13
###begin p 14
###xml 83 86 83 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Farmer1">[8]</xref>
###xml 87 91 87 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Sotiriou1">[11]</xref>
###xml 135 139 135 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Sotiriou1">[11]</xref>
###xml 368 371 368 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Miller1">[9]</xref>
###xml 510 514 510 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Bolstad1">[12]</xref>
###xml 667 674 667 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s009">Text S1</xref>
###xml 604 612 <span type="species:ncbi:9606">patients</span>
###xml 679 686 <span type="species:ncbi:9606">patient</span>
Five datasets of primary breast tumors profiled on Affymetrix HG-U133A microarrays [8]-[11] were used in this meta-analysis. Data from [11] were split into two datasets, those from Uppsala University Hospital (Sotiriou.Uppsala), and the others from the John Radcliffe Hospital who did not receive adjuvant systemic therapy (Sotiriou.JRH.Untreated). HG-U133B data from [9] were excluded. Each dataset was normalized and log2 probe-set intensities calculated using the Robust Multichip Averaging (RMA) algorithm [12]. Subset datasets of Elston-Ellis Grade 3 tumors containing a total of 82 ER- and 101 ER+ patients were then created for use in the meta-analysis (refer Text S1 for patient characteristics).
###end p 14
###begin p 15
###xml 56 60 56 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Richardson1">[13]</xref>
###xml 61 65 61 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Pawitan1">[15]</xref>
###xml 144 151 144 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s009">Text S1</xref>
###xml 177 181 177 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Richardson1">[13]</xref>
###xml 272 277 272 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 378 382 378 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Wang1">[14]</xref>
###xml 425 427 425 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ER</italic>
###xml 454 457 454 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGR</italic>
###xml 471 476 471 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERBB2</italic>
###xml 495 499 495 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRT5</italic>
###xml 590 594 590 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Pawitan1">[15]</xref>
###xml 675 681 675 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 681 685 681 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Sorlie1">[16]</xref>
###xml 697 703 697 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 703 707 703 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Pawitan1">[15]</xref>
Three independent RMA-normalized breast cancer datasets [13]-[15] were used for validation of the meta-analysis and molecular subtype analysis (Text S1). The Richardson dataset [13] of Grade 3 tumors and normal samples, designated tumors as "Basal", "BRCA1" (positive for BRCA1 mutations) or "Non BLC" (non-basal-like cancer) by immunohistochemistry (IHC). For the Wang dataset [14] we used the relative transcript levels of ER (probe set ID 205225_at), PGR (208305_at), ERBB2 (216836_s_at) and KRT5 (201820_at) to identify basal samples. ER status was not available for the Pawitan cohort [15]. These samples had however been classified into the molecular subtypes of Perou et al.[16] by Pawitan et al.[15], (refer the GSE1456 series deposited in the Gene Expression Omnibus ), and these classifications were retained in our study.
###end p 15
###begin title 16
Meta-analysis
###end title 16
###begin p 17
###xml 14 18 14 18 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Choi1">[17]</xref>
###xml 70 78 70 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GeneMeta</italic>
###xml 87 91 87 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Lusa1">[18]</xref>
###xml 561 568 561 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s009">Text S1</xref>
###xml 850 854 850 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Benjamini1">[19]</xref>
###xml 1010 1017 1010 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s009">Text S1</xref>
Meta-analysis [17] was carried out using functions implemented in the GeneMeta package [18]. The change in a gene's expression level between ER+ and ER- tumors in each individual study was expressed as an effect size, which is a unit-free standardized mean difference between conditions measuring the magnitude of a covariate effect corrected for sample size bias. The effect size of each HG-U133A probe set in each dataset was entered into a random effects model which takes into account intra- and inter-study variability to produce a Z score as described in Text S1. A negative Z score indicates a probe set with higher intensity in ER- tumors. The statistical significance of differential expression was calculated by converting the Z scores to P-values which were then adjusted for multiple testing using the Benjamini-Yekutieli (BY) correction [19]. The transformed weighted average ratio (tWAR), which provides an indication of the fold-change between ER+ and ER- tumors, was calculated as described in Text S1.
###end p 17
###begin title 18
Functional annotation analysis
###end title 18
###begin p 19
###xml 194 197 194 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Dennis1">[6]</xref>
###xml 205 212 205 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s009">Text S1</xref>
###xml 420 424 418 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Dahlquist1">[20]</xref>
Sets of selected genes were tested for over-representation of functional annotation categories, including gene ontology (GO) and protein domain categories, using tools within DAVID version 2007 [6] (refer Text S1 for category details). The BY correction for multiple testing was applied to the EASE scores, and the significance threshold set at adjusted P</=0.05. Cell cycle maps were obtained from the GenMapp database [20], and genes within the map colored using tWARs and adjusted P-values from the meta-analysis.
###end p 19
###begin title 20
Statistical analysis of validation datasets
###end title 20
###begin p 21
###xml 171 176 171 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">stats</italic>
###xml 190 194 190 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-R1">[21]</xref>
Complete linkage hierarchical clustering was performed on data scaled so that all probe-sets shared the same mean and variance, using the euclidean distance metric in the stats package in R [21]. The difference in mean probe set intensities between sets of genes in basal and non-basal ER- samples, or between basal and normal samples in the validation data sets was assessed using a two-sided paired t-test. For individual genes of interest, the difference in mean intensity was assessed using a two-sided Welch two-sample t-test.
###end p 21
###begin title 22
###xml 21 22 21 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Analysis of MYC and E2 datasets for differential expression
###end title 22
###begin p 23
###xml 51 57 51 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 57 61 57 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Bild1">[22]</xref>
###xml 71 77 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 77 81 77 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Carroll1">[23]</xref>
###xml 117 123 117 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 123 127 123 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Musgrove1">[24]</xref>
###xml 260 264 260 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Smyth1">[25]</xref>
Transcript profiling data from the studies of Bild et al.[22], Carroll et al.[23] and the in-house study of Musgrove et al.[24] (GSE11791 series deposited in the Gene Expression Omnibus) were RMA-normalized and analyzed for differential expression using LIMMA [25]. No intensity or fold-change filters were used, and the significance threshold for differential expression was set at BY adjusted P<0.05.
###end p 23
###begin title 24
Gene Set Enrichment Analysis (GSEA)
###end title 24
###begin p 25
###xml 5 8 5 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Subramanian1">[7]</xref>
###xml 1078 1079 1078 1079 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
GSEA [7] was used to determine if the members of a given gene set were generally associated with "ER-" tumor status, and was therefore performed on all 22,283 probe sets on the HG-U133A chip ranked by meta-analysis Z score from most negative to most positive. The gene list was collapsed to unique gene symbols using the default capabilities. The maximum gene set size was fixed at 1500 genes, and the minimum size fixed at 15 genes. 1000 random sample permutations were carried out, and the significance threshold set at FDR<0.05. If a gene set had a positive enrichment score, the majority of its members had higher expression in ER- tumors than in ER+ tumors, and the set was termed "enriched" in ER- tumors. If a set had a negative enrichment score it was termed "depleted" in ER- tumors. An initial screening of gene sets enriched in ER- tumors was carried out using the Molecular Signature Database (MolSigDB) c1.v2, c2.v2 and c3.v2 gene sets current as of March 2007 (data not shown). On consideration of the results, other published gene sets relating to the action of E2, MYC and E2Fs were curated and added to the MolSigDB lists in a second GSEA screen.
###end p 25
###begin title 26
Results
###end title 26
###begin title 27
Meta-analysis of ER+ vs. ER- tumors
###end title 27
###begin p 28
###xml 25 29 25 29 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Choi1">[17]</xref>
###xml 496 503 496 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s009">Text S1</xref>
###xml 625 633 625 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s007">Table S1</xref>
A meta-analysis approach [17] was used to obtain overall measures for gene expression in ER+ and ER- tumors from 5 datasets. All datasets consisted of fresh-frozen primary breast cancers profiled on the Affymetrix HG-U133A platform with information on ER status and grade. The meta-analysis was restricted to Grade 3 tumors (82 ER-, 101 ER+), to overcome the association between grade and ER status, and was verified in three independent datasets. Details of the 8 data sets used are provided in Text S1. Measures for ER status association were obtained for all 22,283 HG-U133A probe sets and are presented in the searchable Table S1, of which 2141 (9.6%) were differentially expressed between ER+ and ER- tumors with adjusted P<0.01. This set is referred to as the ER status-associated (ERA) genes.
###end p 28
###begin p 29
###xml 178 187 178 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s002">Figure S1</xref>
To explore whether the results from Grade 3 tumors may be extended to tumors of other grades, we performed a Principal Components Analysis of Grade 2 tumors using the ERA genes (Figure S1). The ERA genes separated the ER+ and ER- Grade 2 tumors indicating that many of the genes differentially expressed in Grade 3 tumors are also differentially expressed in the Grade 2 tumors.
###end p 29
###begin p 30
###xml 126 134 126 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004710-g001">Figure 1</xref>
###xml 798 807 798 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004710-g001">Figure 1A</xref>
###xml 837 846 837 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004710-g001">Figure 1B</xref>
###xml 881 890 881 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004710-g001">Figure 1C</xref>
###xml 1043 1052 1043 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004710-g001">Figure 1B</xref>
The ERA genes were used to cluster the tumors from three independent validation datasets, visualized in the form of heatmaps (Figure 1). In each heatmap, two main gene clusters were produced. The top cluster in each heatmap corresponds to ERA genes that are more highly expressed (red in color) in ER+ tumors and expressed at lower level (blue in color) in ER- tumors. The bottom cluster corresponds to ERA genes that show the converse pattern of expression. The ER status of the tumors is indicated along the top of the heatmap and demonstrates that the ERA gene set can correctly delineate ER+ and ER- tumors in the independent data sets, so validating their intended capacity. Importantly, within the ER- tumors in all three datasets, the ERA genes clearly delineated the basal (Richardson set, Figure 1A), predicted basal (Wang set, Figure 1B) or molecular basal (Pawitan set, Figure 1C) subtypes from the ER-/ERBB2+ subtypes. The expression of ERBB2 is indicated along the top of each heatmap, as is the expression of Keratin 5 (KRT5) in Figure 1B, and appropriate enrichment of these genes in the subtypes is clearly demonstrated. The clustering also distinguished the luminal subtype. Thus the genes that distinguish ER status in our 5 discovery datasets clearly operate in 3 independent datasets to achieve not only the separation of tumors by ER status but also by molecular subtype.
###end p 30
###begin title 31
Hierarchical clustering of ERA genes in cancer samples from A.
###end title 31
###begin p 32
###xml 0 4 0 4 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Richardson1">[13]</xref>
###xml 8 12 8 12 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Wang1">[14]</xref>
###xml 20 24 20 24 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Pawitan1">[15]</xref>
###xml 514 518 514 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Richardson1">[13]</xref>
###xml 771 776 771 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 903 907 903 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Wang1">[14]</xref>
###xml 1196 1217 1196 1217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Materials and Methods</xref>
###xml 1287 1291 1287 1291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Pawitan1">[15]</xref>
###xml 1466 1470 1466 1470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Sorlie1">[16]</xref>
[13], B.[14], and C.[15]. Each row represents a gene; each column represents a sample. The expression level of each gene within a sample, relative to that gene's mean expression across all the samples, is indicated using a red-blue color scale with red indicating high expression. The dendrogram at the top indicates the similarities between the sample expression profiles while the side-dendrogram indicates the similarities between gene expression patterns. Figure 1A data is derived from the Richardson dataset [13] and the top color bars indicate the following: "ER_Protein" - ER status determined using IHC; "PGR_Protein" - PGR status determined using IHC; "ERBB2_Protein" - ERBB2 status determined using IHC; "Subtype" - Subtype determined from IHC results (Basal, BRCA1 mutation positive, or non-basal-like carcinoma ("Non-BLC")) (see sample key). Figure 1B data is derived from the Wang dataset [14] and the top color bars represent the following: "ER_Protein" - ER status as determined using ligand binding assay or IHC; "PGR_Transcript", "ERBB2_Transcript" and "KRT5_Transcript": relative expression measured from quantiles of probe set intensities as described in "Data Collection" in Materials and Methods (see sample key). Figure 1C data is derived from the Pawitan dataset [15] and the top color bars represent the following: "Molecular_Subtype" - determined by correlation to the normal-like, Luminal A, Luminal B, ERBB2+ and basal molecular subtypes [16]; "ER_Transcript"- Relative expression of the HG-U133A ESR1 transcript 205225_at measured in quantiles; "PGR_Transcript", and "ERBB2_Transcript" as above; and "Tumor_Grade" - Elston Ellis grading (see sample key).
###end p 32
###begin title 33
ER- tumors show higher expression of proliferation genes than ER+ tumors of the same grade
###end title 33
###begin p 34
###xml 247 254 247 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004710-t001">Table 1</xref>
###xml 468 476 468 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s008">Table S2</xref>
###xml 632 640 632 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004710-g002">Figure 2</xref>
###xml 665 674 665 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s003">Figure S2</xref>
The ERA genes were analyzed using the "DAVID" tools which test for over-representation of gene ontologies, pathways and protein domains. All 12 categories significantly over-represented in the ERA genes were related to the cell cycle and mitosis (Table 1). These cell-cycle related ERA genes showed predominantly higher expression in ER- tumors, showing that ER- tumors have a higher proliferation rate than ER+ tumors even when the tumors are of the same high grade (Table S2). This is illustrated by an overlay of the meta-analysis results on pathway maps of key cell cycle control genes, namely the "G1 to S Cell cycle control" (Figure 2) and "KEGG Cell Cycle" (Figure S2) maps in the GenMAPP database.
###end p 34
###begin title 35
###xml 67 68 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
Meta-analysis results for genes in the GenMapp representation of "G1 to S-phase Cell Cycle Control".
###end title 35
###begin p 36
Genes are colored by whether they have higher expression in ER+ or ER tumors from the meta-analysis, with the foldchange and significance of this over-expression represented by the transformed Weighted Average Ratio (tWAR) and BY-adjusted P-value (adj P) respectively.
###end p 36
###begin title 37
###xml 44 47 44 47 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Dennis1">[6]</xref>
Functional annotation categories from DAVID [6] significantly over-represented in ERA genes.
###end title 37
###begin p 38
Many categories associated with cell cycle and cell division were significantly over-represented with BY adjusted P<0.05 in the comprehensive ERA gene list.
###end p 38
###begin p 39
###xml 90 96 90 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 127 134 127 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDK2AP1</italic>
###xml 203 207 203 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDK7</italic>
###xml 240 243 240 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAK</italic>
###xml 447 452 447 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ORC1L</italic>
###xml 457 462 457 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ORC6L</italic>
###xml 505 509 505 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MCM2</italic>
###xml 513 517 513 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MCM7</italic>
###xml 523 529 523 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDC45L</italic>
###xml 689 698 689 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s004">Figure S3</xref>
###xml 861 871 861 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s004">Figure S3A</xref>
Within the ERA genes, cyclins A1, A2, B2, E1 and J, cyclin dependent kinase inhibitor 2A (CDKN2A) and CDK2 associated protein (CDK2AP1) show higher expression in ER- tumors whereas cyclins D1, G2 and H, CDK7 and cyclin G-associated kinase (GAK) have higher expression in ER+ tumors. Several genes directly involved in DNA replication are more highly expressed in ER- tumors: for example, those encoding proteins in the origin-recognition complex (ORC1L and ORC6L), the minichromosome maintenance proteins MCM2 to MCM7, and CDC45L. We clustered the genes in the cell cycle categories in the validation datasets, with the samples in forced order first by ER status and then by ERBB2 levels (Figure S3). The differential expression of proliferation associated genes was most pronounced in the basal subgroup of tumors, even when the tumors were of the same grade (Figure S3A), demonstrating the highly-proliferative nature of these tumors compared to other molecular sub types.
###end p 39
###begin title 40
Investigation of the meta-analysis results using GSEA
###end title 40
###begin p 41
###xml 302 306 302 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Xie1">[26]</xref>
###xml 436 446 436 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s001">Dataset S1</xref>
###xml 702 705 702 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 739 740 739 740 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 813 817 813 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Prall1">[27]</xref>
###xml 910 931 910 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Materials and Methods</xref>
###xml 946 947 946 947 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1043 1050 1043 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s010">Text S2</xref>
GSEA is a method that allows us to search the ERA gene set for transcript profiles indicative of underlying biological processes. An initial GSEA study was conducted testing the MolSigDB gene sets pertaining to chromosomal position, curated gene sets from publications, and conserved regulatory motifs [26] for enrichment in the ERA gene set. The complete list of significant associations is viewable by clicking the index.html file in Dataset S1 to launch your browser. Inspection of the results revealed the very prominent enrichment in ER- tumors of many gene sets relating to MYC and E2F activity. Although other themes emerge from this analysis we have concentrated our efforts on these findings. MYC, like cyclin D1, is a target of E2 and can rescue cell proliferation in anti-estrogen arrested MCF-7 cells [27]. We conducted a second GSEA screen after adding extra published and in-house gene sets (see Materials and Methods) relating to E2-, MYC- and E2F-activity in cell-lines, with the added datasets indicated by a prefix of "MCA" (Text S2).
###end p 41
###begin p 42
###xml 37 40 37 40 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Abba1">[4]</xref>
###xml 42 46 42 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-vantVeer1">[28]</xref>
###xml 81 85 81 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-vantVeer1">[28]</xref>
###xml 115 124 115 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s010">Text S2.A</xref>
###xml 164 168 164 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-vantVeer1">[28]</xref>
###xml 186 190 186 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-vantVeer1">[28]</xref>
###xml 441 450 441 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s010">Text S2.B</xref>
###xml 641 642 641 642 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Gene sets associated with ER+ status [4], [28] and good outcome in breast cancer [28] were depleted in ER- tumors (Text S2.A), and genes associated with ER- status [28] and poor outcome [28] were enriched in ER- tumors, showing that the meta-analysis results concur with those of single cohorts. Several gene sets associated with the cell cycle were enriched in ER- tumors, supporting the results from the functional annotation using DAVID (Text S2.B). The gene sets enriched or depleted with false discovery rate (FDR)<0.05 were examined more closely and assigned to biological themes; many sets were associated with chromosomal position, E2-action, MYC action and E2F-action. We report on these categories in detail in subsequent sections.
###end p 42
###begin title 43
Specific cytobands with expression differences between ER+ and ER- tumors
###end title 43
###begin p 44
###xml 93 97 93 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Jones1">[29]</xref>
###xml 99 103 99 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Wang2">[30]</xref>
###xml 226 233 226 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004710-t002">Table 2</xref>
###xml 302 310 302 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s007">Table S1</xref>
###xml 459 463 459 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Bergamaschi1">[31]</xref>
###xml 522 526 522 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Wang2">[30]</xref>
###xml 589 593 589 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Bergamaschi1">[31]</xref>
###xml 662 668 662 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHAF1B</italic>
###xml 673 678 673 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100B</italic>
###xml 912 916 912 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Wang2">[30]</xref>
###xml 1104 1108 1104 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Jones1">[29]</xref>
###xml 1309 1313 1309 1313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Bergamaschi1">[31]</xref>
###xml 1803 1810 1803 1810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004710-t002">Table 2</xref>
DNA copy number alteration shows regional differences between subtypes of ER+ and ER- tumors [29], [30]. Using GSEA, we identified cytoband loci containing sets of genes with expression differences between ER+ and ER- tumors (Table 2); genes in these cytobands are marked in the tables of ERA genes in Table S1. Enriched in ER- tumors were genes within 6p21, 7q32-q33, 10p13 and 21q22 which show gain by comparative genome hybridization (CGH) in basal tumors [31] and 1p34 which shows loss of heterozygosity in ER+ tumors [30]. We note that gain in 21q22 is associated with poor prognosis [31] and that this cytoband contains the cell cycle associated ERA genes CHAF1B and S100B that have elevated expression in ER- tumors. Depleted in ER- tumors were the cytobands 4p16, 5q11-13, 5q22, 5q31, 14q22-23 which show more frequent loss in basal tumors, and 16p11-p13 which shows more frequent gain in luminal tumors [30]. The cytobands 14q11-12, 16p12-13, 17q21 and 17q24 were also depleted in ER- tumors and low resolution CGH mapping suggests that 14q, 16p and 17q have increased loss in basal-like tumors [29]. Genes within 17q21 were generally depleted in ER- tumors, yet amplification of 17q12-21 is common in ERBB2+ tumors, which are usually ER-, and amplification of this region predicts a worse prognosis [31]. Our study delineated novel sites enriched in ER- tumors at the cytobands 2p13, 2p16, 2p21, 2p25, 3q25, 3q29, 6q16, 6q21, 9q21, 11q21-22, 12p13 and 22q13 and depleted in ER- tumors at 3p21, 11q13, and 12q13. These regions may represent previously undetected DNA copy number alterations or epigenetic silencing/reactivation events. ERA genes that had differential expression consistent with enriched/depleted cytobands and are involved in cell cycle and/or cell proliferation are marked in Table 2. Dysregulation of these genes may contribute to the differences in proliferation rates between ER+ and ER- cancers.
###end p 44
###begin title 45
Chromosomal position gene sets enriched or depleted in ER- tumors with FDR<0.05.
###end title 45
###begin p 46
###xml 38 46 38 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s008">Table S2</xref>
Genes are in cell cycle categories in Table S2 and/or the GO0008283 cell proliferation ontology.
###end p 46
###begin title 47
###xml 93 94 93 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Direct transcriptional targets of ER are significantly depleted in ER- tumors, but indirect E2-induced target genes are enriched in ER- tumors
###end title 47
###begin p 48
###xml 141 142 141 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 195 196 195 196 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 385 386 385 386 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 388 397 388 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s010">Text S2.C</xref>
###xml 442 450 442 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s007">Table S1</xref>
###xml 582 583 582 583 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 597 598 597 598 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 624 628 624 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Carroll1">[23]</xref>
###xml 694 695 694 695 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 753 762 753 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s010">Text S2.C</xref>
###xml 784 788 784 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Musgrove1">[24]</xref>
###xml 806 810 806 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Creighton1">[32]</xref>
###xml 886 887 886 887 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 935 944 935 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s010">Text S2.C</xref>
###xml 1035 1036 1035 1036 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1155 1156 1155 1156 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
We expected that much of the gene expression differences between ER+ and ER- tumors might be due to the ability of ER+ tumors to respond to E2. To distinguish the direct and indirect effects of E2 we added datasets of direct ER targets derived by chromatin immunoprecipitation based studies, and datasets containing both direct and indirect targets characterized by early response to E2 (Text S2.C, with genes within these datasets marked in Table S1). Direct ER targets were significantly depleted in ER- tumors (8 sets FDR<0.0001 to 0.023, 1 set = 0.052), with depletion of both E2-induced and E2-repressed direct targets [23] (FDR 0.0013 to 0.021). Surprisingly, sets containing indirectly E2-induced genes were significantly enriched in ER- tumors (Text S2.C) including sets from [24](FDR = 0.015) and [32] (FDR = 0.0047), while several sets of genes down-regulated in response to E2 remained significantly depleted in ER- tumors (Text S2.C). An explanation of these observations may be that transcriptional regulators within the E2 pathway may become activated independently of the ER in ER- tumors, driving the transcription of indirect targets of E2.
###end p 48
###begin title 49
High expression of MYC-induced genes and concomitant low expression of MYC-repressed genes in the basal subgroup
###end title 49
###begin p 50
###xml 11 18 11 18 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004710-t003">Table 3</xref>
###xml 23 32 23 32 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s010">Text S2.D</xref>
###xml 327 331 327 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Bild1">[22]</xref>
###xml 365 369 365 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Musgrove1">[24]</xref>
###xml 475 476 475 476 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 476 480 476 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Musgrove1">[24]</xref>
###xml 582 593 582 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s010">Text S2.D.i</xref>
###xml 716 717 716 717 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 861 868 861 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004710-t004">Table 4</xref>
###xml 272 277 <span type="species:ncbi:9606">human</span>
As seen in Table 3 and Text S2.D, several sets of direct targets of MYC derived from various experimental and tumor systems, genes containing MYC binding motifs and MYC-induced genes, were enriched in ER- tumors. Prominent among these were sets of genes induced by MYC in human primary mammary epithelial cell cultures (HMECs) [22] and in MCF-7 breast cancer cells [24](both with FDR<0.0001). Notably, the subset of MYC-induced genes in MCF-7 cells that was also induced by E2[24] was highly enriched in ER- tumors (FDR<0.0001) and the enrichment plot for this gene set is shown in Text S2.D.i. The enrichment of the MYC-induced genes in MCF-7 cells taken as a whole (FDR<0.0001) was greater than the enrichment of E2-induced genes from the same study (FDR = 0.015). MYC-repressed genes in MCF-7 cells taken as a whole were depleted in ER- tumors (FDR<0.0001) (Table 4).
###end p 50
###begin title 51
Details of MYC- and E2F-related sets enriched in ER- tumors with FDR<0.0001.
###end title 51
###begin p 52
###xml 114 115 114 115 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</underline>
###xml 114 115 114 115 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><underline>U</underline></bold>
###xml 130 131 130 131 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</underline>
###xml 130 131 130 131 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><underline>D</underline></bold>
###xml 174 175 174 175 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</underline>
###xml 174 175 174 175 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><underline>B</underline></bold>
###xml 299 300 299 300 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</underline>
###xml 299 300 299 300 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><underline>M</underline></bold>
Tables are sorted by increasing FDR. The suffixes "U", "D", "B" and "M" refer to whether the genes in the set are Up-regulated or Down-regulated by the molecule in question, Binding Partners (or direct targets) of the molecule identified via chromatin immunoprecipitation (ChIP), or contain Binding Motifs for the molecule in their promoter regions.
###end p 52
###begin title 53
Details of MYC-related sets depleted in ER- tumors with FDR<0.0001.
###end title 53
###begin p 54
###xml 95 96 95 96 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</underline>
###xml 95 96 95 96 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><underline>D</underline></bold>
Tables are sorted by increasing FDR. The suffix "D" refers to whether the genes in the set are Down-regulated by the molecule in question.
###end p 54
###begin p 55
###xml 187 195 187 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s007">Table S1</xref>
###xml 329 337 329 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004710-g003">Figure 3</xref>
###xml 630 631 630 631 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 778 782 778 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Musgrove1">[24]</xref>
###xml 862 866 862 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Zeller1">[33]</xref>
In the ERA genes, 84% of those that were MYC-induced in MCF-7 cells had significantly higher expression in ER- tumors, and 87% that were MYC-repressed had lower expression in ER- tumors (Table S1). We therefore examined, in the three validation datasets, the expression of the ERA genes that were regulated by MYC in MCF7 cells (Figure 3). With the samples forced to order first by ER status and then by ERBB2 level we examined the differential patterns of expression of the Musgrove_Myc_U+D subset of the ERA genes relative to molecular subtype and the ability of this gene set to distinguish directly- and indirectly-regulated E2 and MYC targets. In the left hand side color bars of the heatmaps we have marked the direction of MYC regulation in MCF7 cells (Musgrove_Myc_U+D) [24] as well as the direct targets of MYC defined in B cell lymphoma (Zeller_Myc_B) [33]. Consistent with the results of the meta-analysis and GSEA, the MYC-induced genes were generally higher in ER- tumors and the MYC repressed genes were lower in ER- tumors in all three cohorts. The MYC direct targets followed the same trends as the MYC-regulated genes as a whole.
###end p 55
###begin title 56
###xml 56 60 56 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Musgrove1">[24]</xref>
###xml 91 95 91 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Richardson1">[13]</xref>
###xml 99 103 99 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Wang1">[14]</xref>
###xml 111 115 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Pawitan1">[15]</xref>
Hierarchical clustering of 500 MYC-responsive ERA genes [24] in validation datasets from A.[13], B.[14], and C.[15].
###end title 56
###begin p 57
###xml 186 195 186 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004710-g001">Figure 1A</xref>
###xml 269 270 269 270 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 298 299 298 299 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 612 616 612 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Musgrove1">[24]</xref>
###xml 751 755 751 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Zeller1">[33]</xref>
###xml 838 839 838 839 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 855 859 855 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Musgrove1">[24]</xref>
###xml 958 962 958 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Carroll1">[23]</xref>
The first top color bar of Figure 3A. represents whether the sample is a breast cancer or from normal breast tissue. The remaining top color bars of Figure 3A are equivalent to those in Figure 1A. The colors in the side color bars represent the following: yellow = an E2-induced gene, purple = an E2-repressed gene, orange = a MYC-induced gene, blue = a MYC-repressed gene and red indicates a gene which is a direct target of ER ("ER_B" suffix), or a direct target of MYC ("Myc_B"). Moving from right to left, for each gene, the first side color bar represents the transcriptional response to MYC in MCF-7 cells [24] (Musgrove_Myc_U+D). The next color bar represents whether the gene was classified as being a direct target of MYC in B cell lymphomas [33] (Zeller_Myc_B). The next two color bars represent how this gene was regulated by E2 in MCF-7 cells [24] (Musgrove_E2_U+D), and whether it contained an ER-binding site with 50 kbp of the promoter region [23] (Carroll_ER_50 kbp_B). The top color bars of Figure 3B are equivalent to those of Figure 3B, and the side color bars are the counterparts of those in Figure 3A. The top color bars of Figure 3C. are equivalent to those of Figure 3C, and the side color bars are the counterparts of those in Figure 3A.
###end p 57
###begin p 58
###xml 33 34 33 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 111 115 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Carroll1">[23]</xref>
###xml 148 149 148 149 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 182 186 182 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Musgrove1">[24]</xref>
###xml 431 432 431 432 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 496 497 496 497 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 590 591 590 591 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Since MYC is a direct target of E2, we determined which of these genes are direct targets of ER (Carroll_ER_B) [23], and how they are regulated by E2 in MCF7 cells (Musgrove_E2_U+D) [24]. As shown by the left hand side color bars, and consistent with the GSEA results, the direct targets of ER had higher expression in ER+ tumors in the three validation datasets. Also as expected, many of the MYC-regulated genes overlapped with E2-regulated genes from the same experiment. The overlapping ERA E2-induced and MYC-induced genes had higher expression in ER- tumors, and the overlapping ERA E2-repressed and MYC-repressed genes had lower expression in ER- tumors.
###end p 58
###begin p 59
###xml 184 192 184 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004710-g003">Figure 3</xref>
###xml 373 381 373 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004710-g003">Figure 3</xref>
###xml 429 433 429 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Bild1">[22]</xref>
###xml 480 489 480 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s005">Figure S4</xref>
Importantly, the higher expression of MYC-induced ERA genes was more pronounced in the basal subgroup than in ER- tumors with high ERBB2 expression (P<0.0001 for all three datasets), (Figure 3). Similarly, the lower expression of MYC-repressed ERA genes was generally more pronounced in the basal subgroup than in the ER-/ERBB2+ samples (P<0.0001 for all three datasets), (Figure 3). When ERA genes regulated by MYC in ER- HMECs [22] were used to cluster the validation datasets (Figure S4), we observed very similar results with respect to the basal subtype, demonstrating that the MYC pathway is more active in the basal subgroup and that it mimics estrogen action.
###end p 59
###begin title 60
Genes with E2F binding motifs and direct targets of the E2F family are enriched in ER- tumors
###end title 60
###begin p 61
###xml 113 117 113 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Rowland1">[34]</xref>
###xml 160 164 160 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2F3</italic>
###xml 169 173 169 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2F8</italic>
###xml 283 290 283 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s011">Text S3</xref>
###xml 312 316 312 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2F1</italic>
###xml 321 325 321 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2F5</italic>
###xml 348 352 348 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2F4</italic>
###xml 481 486 481 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TFDP1</italic>
###xml 491 496 491 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TFDP2</italic>
###xml 653 657 653 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Rowland1">[34]</xref>
###xml 700 705 700 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TFDP1</italic>
###xml 728 733 728 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TFDP2</italic>
###xml 775 779 775 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p130</italic>
###xml 1118 1122 1118 1122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2F3</italic>
The E2F family and the proteins that modulate E2F activity are important for cell cycle progression (reviewed in [34]) In the meta-analysis, all probe sets for E2F3 and E2F8 showed significantly higher intensity in ER- tumors (adjusted P<0.0001 and adjusted P = 0.034 respectively) (Text S3). All probe sets for E2F1 and E2F5 and one probe set for E2F4 had higher intensity in ER- tumors (un-adjusted P<0.05), but did not pass the adjusted P significance threshold. Probe sets for TFDP1 and TFDP2, members of the DP transcription factor family, whose products form heterodimers with E2Fs 1 to 6 producing transcription factor complexes that bind to DNA [34], were significantly higher in ER- tumors (TFDP1, adjusted P = 0.0073; TFDP2, adjusted P = 0.0023). One probe set for p130, a pocket protein that binds principally to E2Fs 4 and 5 converting them into repressor complexes, had significantly lower intensity in ER- tumors (adjusted P = 0.0053) with the other probe set showing the same trend. For each gene above, the tWAR, indicating fold-change, was small, with the possible exception of the two probe sets for E2F3 (tWAR = 1.48-fold and 1.88-fold).
###end p 61
###begin p 62
###xml 110 117 110 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004710-t003">Table 3</xref>
###xml 122 131 122 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s010">Text S2.E</xref>
###xml 249 253 249 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Xie1">[26]</xref>
###xml 604 608 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Vernell1">[35]</xref>
###xml 650 657 650 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004710-t003">Table 3</xref>
###xml 761 765 761 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Vernell1">[35]</xref>
In the GSEA screen, several gene sets significantly enriched in ER- tumors were associated with E2F activity (Table 3 and Text S2.E). Nineteen sets contained genes with conserved DNA binding motifs for E2F family members, particularly E2F1 and E2F4 [26]. Different members of the E2F family can bind to the same genes depending on the conditions such as the phase of the cell cycle, and these motif sets had many genes in common. Supporting the observations for genes with conserved E2F motifs, a MolSigDB list of genes up-regulated by E2Fs 1, 2 or 3 and down-regulated by pRB and p16INK4A in U2OS cells [35] was enriched in ER- tumors (FDR<0.0001) (Table 3). The complementary set of genes down-regulated by E2Fs 1, 2 or 3 and up-regulated by pRB and p16INK4A [35] was depleted (FDR = 0.038).
###end p 62
###begin p 63
###xml 234 243 234 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s010">Text S2.E</xref>
###xml 348 355 348 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004710-t003">Table 3</xref>
###xml 418 422 418 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Black1">[36]</xref>
###xml 515 522 515 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004710-t003">Table 3</xref>
###xml 527 536 527 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s010">Text S2.E</xref>
###xml 628 629 628 629 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 629 633 629 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Balciunaite1">[37]</xref>
###xml 644 645 644 645 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 670 674 670 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Balciunaite1">[37]</xref>
###xml 750 754 750 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Ren1">[38]</xref>
###xml 811 815 811 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Ren1">[38]</xref>
###xml 979 980 979 980 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 985 986 985 986 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 986 990 986 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Balciunaite1">[37]</xref>
###xml 1054 1055 1054 1055 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1055 1059 1055 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Balciunaite1">[37]</xref>
###xml 283 288 <span type="species:ncbi:10090">mouse</span>
###xml 727 732 <span type="species:ncbi:9606">human</span>
In order to better understand the roles E2Fs might play in the regulation of proliferation in ER- tumors, we included additional published sets of direct targets of E2Fs 1, 4 and 6, as well as sets of genes regulated by E2F1 or E2F3 (Text S2.E). A list of genes regulated by E2F1 in mouse embryonic fibroblasts (MEFs) was enriched with FDR<0.0001 (Table 3), as was a set of genes regulated by E2F3 from the same study [36]. Several sets of direct targets of E2F1 and E2F4 were significantly enriched in ER- tumors (Table 3 and Text S2.E). The sets enriched with FDR<0.0001 included direct targets of E2F4 in MEFs during either G0[37] or early G1 stage of the cell cycle [37], genes bound by both E2F4 and E2F1 in WI-38 primary human fibroblast cells [38], and genes bound by E2F4 and not E2F1 in the same study [38]. The pocket proteins p130 and p107 bind to E2F4 converting it to a repressor complex, and consistent with this association, direct targets of p130 in MEFs during G0 or G1[37] were enriched with FDR<0.0001, as were targets of p107 during G1[37].
###end p 63
###begin p 64
###xml 189 198 189 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s006">Figure S5</xref>
###xml 473 482 473 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s006">Figure S5</xref>
###xml 572 576 572 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Vernell1">[35]</xref>
###xml 602 606 602 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Black1">[36]</xref>
###xml 898 908 898 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s006">Figure S5A</xref>
To examine if the enrichment of E2F activity differed between the subtypes of ER- tumors, we clustered the validation tumor datasets using ERA genes that were associated with E2F activity (Figure S5). We confirmed that the enriched set of direct targets of E2F4 in MEFs had higher expression in samples with low levels of ER. These genes had particularly high expression in the basal subgroup compared to the ER-/ERBB2+ subgroup in all three datasets (all with P<0.0001), (Figure S5). The ERA genes overlapping with sets of genes activated by E2Fs 1, 2 or 3 in U2OS cells [35], by E2F1 or E2F3 in MEFs [36] and all the enriched gene sets of direct targets of E2Fs 1, 4 or 6 also showed differential expression in the basal tumors (data not shown). ERA genes that were direct targets of E2F4 and over-expressed in basal ER- tumors were also over-expressed with respect to normal tissue (P<0.0001), (Figure S5A).
###end p 64
###begin p 65
To ascertain if the enrichment noted for the MYC and E2F sets was entirely due to the presence of proliferation-associated genes in these sets, we removed genes in the GO "cell cycle" (GO:0007049) and "cell proliferation" (GO:0008283) categories from the relevant sets enriched with FDR<0.0001. GSEA showed that these "proliferation depleted" sets remained as highly enriched as their complete counterparts, and the leading edges of the "proliferation depleted" MYC and E2F sets shared few common genes (data not shown). These results indicate that outside the shared proliferation-associated genes, MYC-action and E2F-action are separate forces contributing independently to the transcriptional differences between ER- and ER+ tumors.
###end p 65
###begin p 66
We also found that the cytobands that were differentially expressed between ER+ and ER- tumors did not contain MYC or genes known to influence MYC-activity (such as the binding partners MAD or MAX). Similarly, the enriched or depleted cytobands did not contain any members of the E2F family that were differentially expressed in the meta-analysis, or any genes known to influence E2F-activity (such as members of the families of DP transcription factors or pocket proteins). It is therefore unlikely that genetic alterations in these regions are the cause of the increased MYC and E2F activity in ER- tumors.
###end p 66
###begin title 67
Discussion
###end title 67
###begin p 68
###xml 349 352 349 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Gruvberger1">[3]</xref>
###xml 353 356 353 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Schneider1">[5]</xref>
###xml 1025 1029 1025 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Sorlie2">[39]</xref>
###xml 1421 1425 1421 1425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Fulford1">[40]</xref>
This study uses a novel meta-analysis approach to identify genes and genetic pathways associated with ER status in breast cancer. Importantly, we restricted our analysis to grade 3 tumors because ER- tumors are almost exclusively of higher grade while ER+ tumors show greater diversity. Thus previously published lists of ER status-associated genes [3]-[5] may contain genes related to grade in addition to ER status. Functional annotation analysis of the 2141 ERA genes using DAVID and GSEA showed that categories associated with cell cycle were enriched in genes up-regulated in ER- tumors compared to ER+ tumors indicating that even at the same grade, ER- tumors exhibit a greater proliferation signal. Hierarchical clustering of the validation datasets revealed that cell-cycle associated genes are more highly expressed in the basal subgroup than in other ER- tumors. While other transcript profiling studies have reported that cell cycle and cell proliferation categories are over-represented in molecular basal tumors [39], they were unable to uncouple the effects of grade and ER status as we have done, due to restricted numbers of samples in their studies. Our results concur with those of a recent histopathological study confined to Grade 3 invasive ductal carcinomas, which found that the basal phenotype was highly significantly associated with high total mitotic count, a marker of increased proliferation [40].
###end p 68
###begin p 69
###xml 64 65 64 65 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 148 149 148 149 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 214 215 214 215 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 345 346 345 346 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 422 425 422 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Abba1">[4]</xref>
###xml 427 431 427 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Lin1">[41]</xref>
###xml 455 456 455 456 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 520 524 520 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Lin1">[41]</xref>
###xml 526 530 526 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Cunliffe1">[42]</xref>
###xml 622 625 622 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Abba1">[4]</xref>
###xml 627 631 627 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Lin1">[41]</xref>
###xml 709 710 709 710 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 793 794 793 794 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 916 917 916 917 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 969 973 969 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Prall1">[27]</xref>
###xml 1028 1029 1028 1029 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1069 1077 1069 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004710-g003">Figure 3</xref>
###xml 1079 1088 1079 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s005">Figure S4</xref>
###xml 1147 1148 1147 1148 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1319 1325 1319 1325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1325 1329 1325 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Creighton1">[32]</xref>
###xml 1418 1419 1418 1419 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
In the GSEA screen, independent lists of direct targets of the E2/ER complex were depleted in ER- tumors as one would expect. The genes induced by E2 in MCF-7 cells in two studies were enriched in ER- tumors, and E2-repressed genes from four studies were depleted in ER- tumors. Consistent with our results, previous studies aiming to identify E2-induced genes over-expressed in ER+ tumors found fewer genes than expected [4], [41], and small subsets of E2-induced genes were observed to be over-expressed in ER- tumors [41], [42]. These apparent discrepancies were attributed to differences between tumors and cell lines [4], [41]. Our results provide an alternative explanation: aberrant activation of the E2-target MYC leads to a robust induction of a subset of genes characteristic of an E2 response. Consistent with this hypothesis, MYC is capable of rescuing cell cycle progression in MCF-7 cells arrested in G1 phase by pre-treatment with an estrogen antagonist [27] and a large proportion of the ERA genes regulated by E2 in MCF-7 cells are also MYC-regulated (Figure 3, Figure S4 and associated references). Unlike the direct targets of E2, both the direct targets of MYC in B-cell lymphoma and genes containing MYC binding motifs were enriched in ER- tumors. Our results support and extend those of Creighton et al.[32] who reported that a single list of genes which showed early and sustained induction by E2 in ER+ cell lines (labeled as "MCA.Creighton.Cluster B Genes_E2_Early.Sustained_U" in our GSEA screen) was enriched in ER- tumors in a cohort of Grade 1 to 3 tumors.
###end p 69
###begin p 70
###xml 16 19 16 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 101 105 101 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-McNeil1">[43]</xref>
###xml 147 150 147 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 263 267 263 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Naidu1">[44]</xref>
###xml 269 272 269 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 351 355 351 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Cuny1">[45]</xref>
###xml 420 424 420 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-RodriguezPinilla1">[46]</xref>
###xml 447 450 447 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 540 544 540 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Naidu1">[44]</xref>
###xml 546 550 546 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Blancato1">[47]</xref>
###xml 559 565 559 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 565 569 565 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Rhodes1">[48]</xref>
###xml 636 640 636 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Bild1">[22]</xref>
A wide range of MYC transcript levels by RT-PCR has been detected in both ER+ and ER- breast cancers [43]. In our meta-analysis, the expression of MYC was significantly higher in ER- tumors (adjusted P = 0.024), corroborating the results of a single cohort study [44]. MYC copy number amplification is associated with loss of ER and PGR in one cohort [45] and is not associated with ER positive status in another cohort [46]. Amplification of the MYC gene and/or over-expression of MYC protein is associated with high grade in some cohorts [44], [47]. Rhodes et al.[48] reported the presence of a set of genes activated by MYC in HMECs [22] in signatures of Grade 3 breast cancer.
###end p 70
###begin p 71
###xml 29 32 29 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 131 134 131 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 177 182 177 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 238 242 238 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Adem1">[49]</xref>
###xml 264 267 264 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 311 315 311 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-RodriguezPinilla1">[46]</xref>
###xml 363 366 363 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 426 429 426 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 1092 1095 1092 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 1282 1285 1282 1285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 1383 1387 1383 1387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Efstratiadis1">[50]</xref>
We observed higher levels of MYC transcripts in the basal subtype compared to ER-/ERBB2+ samples in two of our validation cohorts. MYC is significantly amplified in tumors with BRCA1 mutations which have a profile similar to basal tumors [49] but amplification of MYC is not correlated with the basal phenotype [46], suggesting that the high transcript levels of MYC we observed in ER- tumors may be due to factors other than MYC amplification. By classifying samples in the validation cohorts into the predicted subtypes of breast cancer, we made the novel observation that the elevated expression of MYC-induced genes, including MYC direct targets, and the lower expression of MYC-repressed genes distinguishes the basal subgroup of ER- tumors. Furthermore, in a concurrent study from this laboratory, we have also observed that expression of c-Myc with a predominant cytoplasmic staining pattern on IHC significantly correlates with the basal phenotype as determined by an ER-/PGR-/ERBB2-/KRT5/6+ staining pattern (McNeil CM, Musgrove EA and Sutherland RL, manuscript in preparation). The MYC transcript was over-expressed in the basal subtype compared to ER-/ERBB2+ samples in two of our validation cohorts, Richardson P = 0.036, Pawitan P = 0.00013, but not in Wang P = 0.964. MYC over-expression in basal cancer in other datasets can be distinguished on the basis of frequency [50], but our analysis of the five meta-analysis datasets indicates that it is not a prominent feature, ranking below the top 1000 differentially expressed mRNAs. Thus the strong transcriptional effect of MYC that we have detected suggests that more than altered MYC expression is contributing to its activity in basal breast cancer.
###end p 71
###begin p 72
###xml 303 307 303 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Rowland1">[34]</xref>
###xml 746 750 746 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Leone1">[51]</xref>
###xml 767 771 767 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Ogawa1">[52]</xref>
###xml 885 889 885 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Zeller1">[33]</xref>
###xml 891 895 891 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Ogawa1">[52]</xref>
###xml 901 904 901 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 956 957 956 957 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 968 969 968 969 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 979 983 979 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Balciunaite1">[37]</xref>
###xml 1037 1041 1037 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Ren1">[38]</xref>
###xml 1043 1047 1043 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2F3</italic>
###xml 1049 1053 1049 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2F5</italic>
###xml 1058 1063 1058 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TFDP1</italic>
###xml 1147 1151 1147 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Musgrove1">[24]</xref>
###xml 1160 1166 1160 1166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1166 1170 1166 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Zeller1">[33]</xref>
###xml 1754 1760 1754 1760 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1760 1764 1760 1764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Kreike1">[53]</xref>
###xml 2084 2090 2084 2090 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 2090 2094 2090 2094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Kreike1">[53]</xref>
###xml 2320 2324 2320 2324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Bild1">[22]</xref>
###xml 2450 2454 2450 2454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Rhodes1">[48]</xref>
###xml 2599 2603 2599 2603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004710-Rhodes1">[48]</xref>
###xml 1019 1024 <span type="species:ncbi:9606">human</span>
Our study also highlights the role of the E2F family in ER- tumors, and shows that their dysregulation may play a role in the proliferation of basal tumors. E2Fs are known to control the expression of genes important for cell cycle progression as well as genes involved in apoptosis and differentiation [34]. E2F binding motif gene sets were enriched, as were several lists of direct targets for E2F1, 4 and/or 6. As E2F family members overlap considerably in their binding specificity, we conclude that the direct binding of one or more members of the E2F family is increased in ER- tumors, but cannot specify which family member. The actions of the E2F family members are closely linked with those of MYC. The MYC protein can regulate the E2Fs [51], and vice versa [52]. Many of the genes regulated by various E2Fs during the early events of the cell cycle are also regulated by MYC [33], [52]. The MYC gene is bound by E2F4 but not p130 or p107 during G0 (but not G1) in MEFs [37]. MYC is a direct target of E2F1 in human fibroblasts [38]. E2F3, E2F5 and TFDP1, which have higher expression in ER- tumors, are all induced by MYC in MCF-7 cells [24]. Zeller et al.[33] found the E2F1 binding motif is enriched 16-fold in clusters of MYC-binding genes, and 37-fold within the subset of E-box containing genes. In our study, the genes shared between gene sets relating to MYC- and E2F-action were predominantly proliferation-associated genes. In this context, we believe that dysregulation or constitutive activation of processes regulated by MYC in conjunction with increased E2F activity may lead to uncontrolled cell cycle progression and proliferation, such as we see in ER- tumors and particularly in the basal subtype within the ER- tumors. Kreike et al.[53] showed that the basal subtype may be further divided into five subgroups on the basis of gene expression profiles. A group of proliferation-associated genes was among those contributing to the clustering. The enrichment of MYC- and E2F-regulated genes in the genes partitioning the basal tumors in the cohort of Kreike et al.[53] may prove a valuable avenue of investigation. Our findings may also have important therapeutic implications. A recent bioinformatic study indicated a significant association between the set of genes activated by MYC in HMECs [22], and genes repressed on treatment of MCF-7 or HL-60 cells with the PI3K signaling pathway inhibitors wortmannin or LY-294002 [48]. MYC-activated genes had lower expression in cells treated with wortmannin or LY-294002, suggesting that PI3K inhibitors repress MYC-activation [48]. Our study provides strong evidence for MYC-action in basal tumors, suggesting that PI3K inhibitors, and other potential repressors of MYC-action, should be investigated as therapeutic candidates for these tumors which have no targeted therapies at present. We anticipate that the biological insights generated by this study will prove valuable in the development of new therapeutic strategies for the poor prognosis ER- tumors and in particular the basal subtype. We conclude that over-expression or constitutive activation of MYC, possibly in conjunction with elevated E2F activity, may contribute to increased proliferation in ER- breast tumors, particularly in the basal subgroup.
###end p 72
###begin title 73
Supporting Information
###end title 73
###begin p 74
GSEA results from first screen. The file contains a zipped archive of the HTML results of the second GSEA screen. Reports for enriched or depleted datasets may be accessed from the "index.html" link within the my_analysis.GseaPreranked.1219975950625.rpt.zip ZIP archive. Enrichment plots are available for each of the 50 most enriched and depleted gene sets.
###end p 74
###begin p 75
(13.32 MB ZIP)
###end p 75
###begin p 76
Click here for additional data file.
###end p 76
###begin p 77
###xml 542 551 542 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s002">Figure S1</xref>
###xml 677 686 677 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s002">Figure S1</xref>
Principal components analyses (PCAs) using ERA genes on Grade 3 and Grade 2 ER+ and ER- samples. The ERA genes were identified by a meta-analysis of Grade 3 samples in five datasets (Farmer, Sotiriou.JRH.Untreated, Miller, Minn and Sotiriou.Uppsala). To demonstrate that these ERA genes also separate Grade 2 ER+ and ER- tumors, PCAs using the ERA genes were performed on Grade 2 samples from those same five datasets. The PCAs of Grade 3 samples in the Farmer, Sotiriou.JRH.Untreated, Miller, Minn and Sotiriou.Uppsala datasets are found in Figure S1A.i-v; PCAs of Grade 2 samples in the Farmer, Sotiriou.JRH.Untreated, Miller, Minn and Sotiriou.Uppsala datasets are found in Figure S1B.i-v.
###end p 77
###begin p 78
(0.54 MB TIF)
###end p 78
###begin p 79
Click here for additional data file.
###end p 79
###begin p 80
Meta-analysis results for genes in the GenMapp representation of KEGG Cell Cycle. Genes are colored by whether they have higher expression in ER+ or ER tumors from the meta-analysis, with the foldchange and significance of this over-expression represented by the transformed Weighted Average Ratio (tWAR) and BY-adjusted P-value (adj P) respectively.
###end p 80
###begin p 81
(0.08 MB TIF)
###end p 81
###begin p 82
Click here for additional data file.
###end p 82
###begin p 83
###xml 239 247 239 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004710-g001">Figure 1</xref>
###xml 667 677 667 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s004">Figure S3A</xref>
###xml 1183 1193 1183 1193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s004">Figure S3B</xref>
###xml 1557 1578 1557 1578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Materials and Methods</xref>
###xml 1597 1607 1597 1607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s004">Figure S3C</xref>
Hierarchical clustering of expression data from cell-cycle-associated genes in datasets from A. Richardson et al. (2006), B. Wang et al. (2005), and C. Pawitan et al. (2005). The two-way clustering of the ERA genes and samples previously (Figure 1) had indicated that the ERA genes were differentially expressed between the ER+, basal and ER-/ERBB2+ tumor subtypes. In order to clarify the behavior of the cell-cycle-associated genes in the different subtypes, we ordered the samples in the validation datasets primarily by ER status and secondarily by ERBB2 status, and then clustered only the cell-cycle-associated genes while maintaining the order of the samples. Figure S3A data is derived from the Richardson dataset (Richardson et al., 2006) and the top color bars indicate the following: "Sample Type" - whether the sample is a breast cancer or from normal breast tissue; "ER_Protein" - ER status determined using IHC; "PGR_Protein" - PGR status determined using IHC; "ERBB2_Protein" - ERBB2 status determined using IHC; "Subtype" - Subtype determined from IHC results (Basal, BRCA1 mutation positive, non-basal-like carcinoma ("Non-BLC"), or Normal tissue) (see sample key). Figure S3B. data is derived from the Wang dataset (Wang et al. 2005) and the top color bars represent the following: "ER_Protein" - ER status as determined using ligand binding assay or IHC; "ER_Transcript", "PGR_Transcript", "ERBB2_Transcript" and "KRT5_Transcript": relative expression measured from quantiles of probe set intensities as described in "Data Collection" in Materials and Methods (see sample key). Figure S3C. data is derived from the Pawitan dataset (Pawitan et al. 2005) and the top color bars represent the following: "Molecular_Subtype" - determined by correlation to the normal-like, Luminal A, Luminal B, ERBB2+ and basal molecular subtypes (Sorlie et al. 2001); "ER_Transcript", "PGR_Transcript", and "ERBB2_Transcript" as above; and "Tumor_Grade" - Elston Ellis grading (see sample key). Two major clusters of cell-cycle-associated genes were observed in all three heatmaps; in each dataset, the highest expression of cell-cycle genes was observed in the basal samples, as marked.
###end p 83
###begin p 84
(0.36 MB TIF)
###end p 84
###begin p 85
Click here for additional data file.
###end p 85
###begin p 86
###xml 395 405 395 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s005">Figure S4A</xref>
###xml 453 463 453 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s004">Figure S3A</xref>
###xml 1518 1528 1518 1528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s005">Figure S4B</xref>
###xml 1556 1566 1556 1566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s004">Figure S3B</xref>
###xml 1625 1635 1625 1635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s005">Figure S4A</xref>
###xml 1659 1669 1659 1669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s005">Figure S4C</xref>
###xml 1697 1707 1697 1707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s004">Figure S3C</xref>
###xml 1766 1776 1766 1776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s005">Figure S4A</xref>
Hierarchical clustering of expression data from 130 MYC-responsive ERA genes (Bild et al., 2006) in datasets from A. Richardson et al. (2006), B. Wang et al. (2005), and C. Pawitan et al. (2005). The ERA Bild_MYC_U+D genes are ERA genes that were also regulated by MYC in HMECs (Bild et al. 2006). We clustered these genes in the three validation datasets while maintaining the sample order. In Figure S4A, the top color bars are equivalent to those of Figure S3A. The colors in the side color bars represent the following: yellow = an E2-induced gene, purple = an E2-repressed gene, orange = a MYC-induced gene, blue = a MYC-repressed gene and red indicates a gene which is a direct target of ER ("ER_B" suffix), or a direct target of MYC ("Myc_B"). Moving from right to left, for each gene, the first two side color bars represent the transcriptional response to MYC in HMECs (Bild et al., 2006) (Bild_MYC_U+D), and in MCF-7 cells (Musgrove et al., 2008; McNeil et al., 2006) (Musgrove_Myc_U+D). The next color bar represents whether the gene was classified as being a direct target of MYC in B cell lymphomas (Zeller et al., 2006) (Zeller_Myc_B). The next three color bars represent how this gene was regulated by E2 in MCF-7 cells at 6 hours (Musgrove et al., 2008; McNeil et al., 2006) (Musgrove_E2_U+D), and at 3 hours (Carroll et al., 2006) (Carroll_3 hr_E2_U+D), and whether it contained an ER-binding site with 50 kbp of the promoter region (Carroll et al., 2006) (Carroll_ER_50 kbp_B). The top color bars of Figure S4B are equivalent to those of Figure S3B, and the side color bars are the counterparts of those in Figure S4A. The top color bars of Figure S4C are equivalent to those of Figure S3C, and the side color bars are the counterparts of those in Figure S4A. It can be seen that the majority of ERA MYC-induced genes have higher expression in the basal tumors, and the majority of ERA MYC-repressed genes have lower expression in basal tumors.
###end p 86
###begin p 87
(0.48 MB TIF)
###end p 87
###begin p 88
Click here for additional data file.
###end p 88
###begin p 89
###xml 314 323 314 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s006">Figure S5</xref>
###xml 362 385 362 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s006">Figure S5A, S5B and S5C</xref>
###xml 425 448 425 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004710.s004">Figure S3A, S3B and S3C</xref>
###xml 255 260 <span type="species:ncbi:10090">mouse</span>
Hierarchical clustering of MCA.Baliciunate_E2F4.G0_B ERA genes (Baliciunate et al., 2005) in datasets from A. Richardson et al. (2006), B. Wang et al. (2005), and C. Pawitan et al. (2005). The MCA.Baliciunate_E2F4.G0_B genes are direct targets of E2F4 in mouse embryonic fibroblasts (Baliciunate et al., 2005). In Figure S5, the top color bars are equivalent of Figure S5A, S5B and S5C are equivalent to those of to those of Figure S3A, S3B and S3C respectively.
###end p 89
###begin p 90
(0.35 MB TIF)
###end p 90
###begin p 91
Click here for additional data file.
###end p 91
###begin p 92
The HG-U133A probe sets and their biological associations. A zipped EXCEL spreadsheet containing all 22,283 HG-U133A probe sets, along with Probe Set ID, Representative public database IDs (RefSeq transcript, Entrez, and Unigene), Gene Name, Gene Symbol, Z score, BY-adjusted P-value, status as an ERA gene, transformed Weighted Average Ratio, as well as whether they have an association with, E2-action, MYC-action, E2F-action, the cell cycle or significantly enriched or depleted chromosomal position in several different datasets. A negative "Overall Z score" indicates a probe set with higher intensity in ER- tumors.
###end p 92
###begin p 93
(3.78 MB ZIP)
###end p 93
###begin p 94
Click here for additional data file.
###end p 94
###begin p 95
Cell cycle genes over-expressed in ER- or ER+ tumors. Cell cycle associated genes, and their over-expression in ER- tumors or ER+ tumors from the meta-analysis.
###end p 95
###begin p 96
(0.02 MB PDF)
###end p 96
###begin p 97
Click here for additional data file.
###end p 97
###begin p 98
Supplementary Methods
###end p 98
###begin p 99
(0.10 MB DOC)
###end p 99
###begin p 100
Click here for additional data file.
###end p 100
###begin p 101
Behavior of major biological categories enriched or depleted in ER- tumors in GSEA. Tables are sorted by increasing FDR. Gene sets linked with Estrogen (E2), MYC or E2F activity have been labeled with suffixes "U", "D", "B", "Dir" and "M" referring to whether the genes in the set are Up-regulated or Down-regulated by the molecule in question, Binding Partners (or direct targets) of the molecule identified via ChIP, other Direct targets of the molecule identified by the use of cycloheximide, or whether they contain conserved Binding Motifs for the molecule in their promoter regions.
###end p 101
###begin p 102
(0.47 MB DOC)
###end p 102
###begin p 103
Click here for additional data file.
###end p 103
###begin p 104
Behavior of probe sets for MYC, E2F and associated genes in the meta-analysis.
###end p 104
###begin p 105
(0.09 MB DOC)
###end p 105
###begin p 106
Click here for additional data file.
###end p 106
###begin p 107
We are grateful to Marcelo Sergio (Garvan Institute of Medical Research) for assistance with the MCF-7 dataset, and Warren Kaplan (Garvan Institute of Medical Research) for technical assistance. We also thank Roger Daly, Catriona McNeil and Tilman Brummer (all of the Garvan Institute of Medical Research), along with Jason Carroll (Cancer Research UK Cambridge Research Institute) for useful discussion. We are indebted to all research groups who made their microarray data publicly available.
###end p 107
###begin p 108
###xml 0 17 0 17 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Manuscript Notes:</bold>
Manuscript Notes: Searchable PDFs of hierarchical clustering images with gene symbols, lists of genes added to the Gene Set Enrichment Analysis (GSEA), and the complete GSEA results for the second screen are available on request.
###end p 108
###begin title 109
References
###end title 109
###begin article-title 110
Origins of breast cancer subtypes and therapeutic implications.
###end article-title 110
###begin article-title 111
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
###end article-title 111
###begin article-title 112
Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns.
###end article-title 112
###begin article-title 113
Gene expression signature of estrogen receptor alpha status in breast cancer.
###end article-title 113
###begin article-title 114
Identification and meta-analysis of a small gene expression signature for the diagnosis of estrogen receptor status in invasive ductal breast cancer.
###end article-title 114
###begin article-title 115
DAVID: Database for Annotation, Visualization and Integrated Discovery.
###end article-title 115
###begin article-title 116
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles.
###end article-title 116
###begin article-title 117
Identification of molecular apocrine breast tumours by microarray analysis.
###end article-title 117
###begin article-title 118
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 117 124 <span type="species:ncbi:9606">patient</span>
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.
###end article-title 118
###begin article-title 119
Genes that mediate breast cancer metastasis to lung.
###end article-title 119
###begin article-title 120
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
###end article-title 120
###begin article-title 121
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias.
###end article-title 121
###begin article-title 122
###xml 42 47 <span type="species:ncbi:9606">human</span>
X chromosomal abnormalities in basal-like human breast cancer.
###end article-title 122
###begin article-title 123
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.
###end article-title 123
###begin article-title 124
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.
###end article-title 124
###begin article-title 125
Gene expression pattern of breast carcinomas distinguish tumor subclasses with clinical implications.
###end article-title 125
###begin article-title 126
Combining multiple microarray studies and modeling interstudy variation.
###end article-title 126
###begin article-title 127
GeneMeta: MetaAnalysis for High Throughput Experiments.
###end article-title 127
###begin article-title 128
The control of the false discovery rate in multiple testing under dependency.
###end article-title 128
###begin article-title 129
GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways.
###end article-title 129
###begin article-title 130
###xml 32 37 <span type="species:ncbi:9606">human</span>
Oncogenic pathway signatures in human cancers as a guide to targeted therapies.
###end article-title 130
###begin article-title 131
Genome-wide analysis of estrogen receptor binding sites.
###end article-title 131
###begin article-title 132
Identification of Functional Networks of Estrogen- and c-Myc-Responsive Genes and Their Relationship to Response to Tamoxifen Therapy in Breast Cancer.
###end article-title 132
###begin article-title 133
Limma: linear models for microarray data.
###end article-title 133
###begin article-title 134
###xml 45 50 <span type="species:ncbi:9606">human</span>
Systematic discovery of regulatory motifs in human promoters and 3[prime] UTRs by comparison of several mammals.
###end article-title 134
###begin article-title 135
c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry.
###end article-title 135
###begin article-title 136
Gene expression profiling predicts clinical outcome of breast cancer.
###end article-title 136
###begin article-title 137
Molecular Cytogenetic Identification of Subgroups of Grade III Invasive Ductal Breast Carcinomas with Different Clinical Outcomes.
###end article-title 137
###begin article-title 138
Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers.
###end article-title 138
###begin article-title 139
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.
###end article-title 139
###begin article-title 140
###xml 115 120 <span type="species:ncbi:9606">human</span>
Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors.
###end article-title 140
###begin article-title 141
###xml 66 71 <span type="species:ncbi:9606">human</span>
Global mapping of c-Myc binding sites and target gene networks in human B cells.
###end article-title 141
###begin article-title 142
Re-Evaluating Cell-Cycle Regulation by E2Fs.
###end article-title 142
###begin article-title 143
Identification of Target Genes of the p16INK4A-pRB-E2F Pathway.
###end article-title 143
###begin article-title 144
Distinctions in the specificity of E2F function revealed by gene expression signatures.
###end article-title 144
###begin article-title 145
Pocket Protein Complexes Are Recruited to Distinct Targets in Quiescent and Proliferating Cells.
###end article-title 145
###begin article-title 146
E2F integrates cell cycle progression with DNA repair, replication, and G2/M checkpoints.
###end article-title 146
###begin article-title 147
Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: Gene expression analyses across three different platforms.
###end article-title 147
###begin article-title 148
Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast.
###end article-title 148
###begin article-title 149
Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells.
###end article-title 149
###begin article-title 150
The gene expression response of breast cancer to growth regulators: patterns and correlation with tumor expression profiles.
###end article-title 150
###begin article-title 151
c-Myc overexpression and endocrine resistance in breast cancer.
###end article-title 151
###begin article-title 152
Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction.
###end article-title 152
###begin article-title 153
Relating Genotype and Phenotype in Breast Cancer: An Analysis of the Prognostic Significance of Amplification at Eight Different Genes or Loci and of p53 Mutations.
###end article-title 153
###begin article-title 154
MYC amplification in breast cancer: a chromogenic in situ hybridisation study.
###end article-title 154
###begin article-title 155
Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses.
###end article-title 155
###begin article-title 156
Molecular concepts analysis links tumors, pathways, mechanisms, and drugs.
###end article-title 156
###begin article-title 157
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERBB2</italic>
###xml 6 10 6 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TBX2</italic>
###xml 12 19 12 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RPS6KB1</italic>
###xml 25 28 25 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 62 67 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 72 77 72 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
ERBB2,TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers.
###end article-title 157
###begin article-title 158
Notch, Myc and Breast Cancer.
###end article-title 158
###begin article-title 159
Myc Requires Distinct E2F Activities to Induce S Phase and Apoptosis.
###end article-title 159
###begin article-title 160
A Complex with Chromatin Modifiers That Occupies E2F- and Myc-Responsive Genes in G0 Cells.
###end article-title 160
###begin article-title 161
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.
###end article-title 161
###begin article-title 162
Functional validation of genes implicated in lymphomagenesis: an in vivo selection assay using a Myc-induced B-cell tumor.
###end article-title 162
###begin p 163
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 163
###begin p 164
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: Work in these laboratories is supported by grants from the Cancer Institute NSW, National Health and Medical Research Council of Australia (NH&MRC), the Petre Foundation and the RT Hall Trust. MCA is the recipient of an Australian Postgraduate Award. MGG is supported by a Cancer Institute NSW Infrastructure grant. DJN was supported by an Australian Research Council grant for the duration of this work. YW is funded internally by Veridex, Johnson & Johnson. JAF is funded by the Netherlands Genomics Initiative/Netherlands Organisation for Scientific Research. RLS is a Senior Principal Research Fellow of the NH&MRC. EAM is a Cancer Institute NSW Fellow. CJO is a Senior Research Fellow of the NH&MRC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 164

